Market capitalization | $1.08b |
Enterprise Value | $1.11b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 36.50 |
P/S ratio (TTM) P/S ratio | 35.58 |
P/B ratio (TTM) P/B ratio | 99.69 |
Revenue growth (TTM) Revenue growth | 135.59% |
Revenue (TTM) Revenue | $30.47m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
11 Analysts have issued a AnaptysBio, Inc. forecast:
11 Analysts have issued a AnaptysBio, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 30 30 |
135%
135%
|
|
Gross Profit | 28 28 |
166%
166%
|
|
EBITDA | -153 -153 |
11%
11%
|
EBIT (Operating Income) EBIT | -155 -155 |
11%
11%
|
Net Profit | -170 -170 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Daniel Faga |
Employees | 117 |
Founded | 2005 |
Website | www.anaptysbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.